The follow-on investment shall strengthen Cipla's partnership with Achira, enabling penetration into business domain of designing, developing and manufacturing microfluidics based PoC immunoassay and molecular assay technologies.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content